If your dog has developed red bumps, pimples, circular crusts, or patchiness in their coat—often accompanied by a greasy feel and a distinctive, unpleasant odor—you are likely dealing with pyoderma. Pyoderma is a bacterial skin infection that is among the most common diagnoses in small-animal veterinary medicine. In fact, it is the single most frequent reason antimicrobials are prescribed for companion animals.

When confronted with a flare-up of red, itchy skin, the historical default for many owners and practitioners has been to reach for an oral antibiotic pill. However, veterinary dermatology has undergone a major paradigm shift. Driven by the dramatic rise of multidrug-resistant bacteria, specifically methicillin-resistant Staphylococcus pseudintermedius (MRSP), international guidelines now strongly advocate for a "topical-first" approach for superficial infections.

This guide walks you through the clinical staging of pyoderma, the diagnostic steps your veterinarian should take, the tiered system of antibiotic selection, and how to execute an effective topical treatment plan. Crucially, it also presents new, reproducible resistance data from the FDA's national veterinary diagnostic surveillance program to show exactly why topical therapy is no longer just an alternative—it is the safest and most effective first-line clinical standard.

The short answer, first

Pyoderma is a bacterial skin infection, almost always caused by Staphylococcus pseudintermedius, a normal resident of canine skin and mucous membranes that overgrows when the skin barrier is compromised. It is not contagious to healthy humans or other pets. Pyoderma is rarely a primary disease; it is almost always a secondary sign of an underlying trigger such as environmental allergies, food allergies, flea allergy dermatitis, endocrine disorders (hypothyroidism or Cushing's disease), or parasitic infestations like demodectic mange.

Current guidelines from the International Society for Companion Animal Infectious Diseases (ISCAID, 2025), building on the earlier World Association for Veterinary Dermatology (WAVD) consensus, establish topical therapy as the first-line recommended standard for superficial pyoderma. Medicated shampoos (specifically 2% to 4% chlorhexidine) and daily sprays or wipes are as effective as oral antibiotics, regardless of whether the bacteria are methicillin-resistant (MRSP) or methicillin-susceptible (MSSP).

Oral systemic antibiotics (such as cephalexin, clindamycin, cefpodoxime, or Convenia) are reserved for deep infections, cases with poor compliance, or when topical therapy is logistically impossible. Under the current 2025 ISCAID pyoderma guidelines, systemic therapy starts at roughly 2 weeks for superficial pyoderma and 3 weeks for deep pyoderma, followed by a recheck exam to decide whether to continue — a deliberate move away from the older fixed 3-week and 6-week courses. The traditional rule of extending treatment until 7 to 14 days past complete clinical resolution still guides how long to continue if lesions have not fully cleared at recheck. Empirical prescribing should be avoided for recurrent cases; instead, a skin culture is mandatory to guide therapy, as roughly 36.5% of canine staphylococcal isolates submitted to diagnostic laboratories are now resistant to methicillin/oxacillin.

What is Staphylococcus pseudintermedius, and how does it cause pyoderma?

To manage pyoderma effectively, you must understand that the bacteria causing the infection are likely already living on your dog. In humans, the dominant skin staph is Staphylococcus aureus. In dogs, it is Staphylococcus pseudintermedius.

S. pseudintermedius is an opportunistic pathogen. It resides harmlessly in the nasal passages, oral cavity, and perineal region of healthy dogs, playing a role in the normal microbial community of the skin. It does not cause disease until a change in the microenvironment of the skin allows it to colonize and multiply rapidly.

Common events that disrupt the skin barrier include:

• Physical trauma: Scratching, chewing, or rubbing due to allergy-induced itching.
• Excess moisture: Skin folds (in brachycephalic breeds), frequent swimming, or poor grooming.
• Chemical changes: Using human shampoos or harsh chemicals that alter the natural pH of canine skin (which is more alkaline than human skin).
• Immunological suppression: Systemic disease, stress, or the inappropriate use of immunosuppressive drugs like corticosteroids.

Once the barrier is breached, S. pseudintermedius adheres to the outermost cells of the skin, secretes toxins and enzymes that degrade tissue, and triggers an inflammatory response. The result is the classic presentation of pyoderma.

Zoonotic risk: Is my dog contagious?

A common concern among pet owners is whether they or their other pets can catch pyoderma from an infected dog.

Because S. pseudintermedius is highly adapted to colonize dogs, it poses a very low zoonotic risk to healthy humans. It is not contagious in the way that ringworm (a fungal infection) is. Healthy adults and children can safely handle and groom a dog with pyoderma, provided normal hand hygiene is practiced.

However, caution is warranted in specific circumstances:

• Immunocompromised individuals: People undergoing chemotherapy, taking immunosuppressive medications, or with severe chronic illness should consult their physician before managing a dog with pyoderma.
• Open wounds: If you have open cuts, scrapes, or active eczema, avoid letting the infected areas of your dog's skin come into contact with your bare skin.
• MRSP carriage: Methicillin-resistant S. pseudintermedius (MRSP) can transiently colonize humans. While it rarely causes disease in healthy people, humans can act as mechanical vectors, carrying the resistant bacteria from an infected dog to other vulnerable animals.

Among other household pets, healthy dogs and cats are unlikely to contract pyoderma from a housemate because their own skin barriers prevent colonization. However, if a second pet has active allergies or skin lesions, they are at higher risk of secondary colonization from the increased bacterial load in the shared environment.

---

Staging: Surface, Superficial, and Deep Pyoderma

Veterinarians classify pyoderma based on the depth of the infection within the skin structure. Staging is critical because it dictates the choice of treatment, the duration of therapy, and the prognosis.

Staging	Depth / Tissue Involved	Common Clinical Signs	Primary Treatment Strategy
Surface Pyoderma	Confined to the outermost layer of the epidermis (stratum corneum). No follicular involvement.	Moist eczema (hot spots), skin fold pyoderma (intertrigo), mucocutaneous pyoderma.	Strictly topical therapy. Systemic antibiotics are contraindicated.
Superficial Pyoderma	Involves the epidermis and the hair follicles (bacterial folliculitis).	Papules, pustules, epidermal collarettes (circular crusts with peeling edges), circular hair loss ("moth-eaten" appearance).	Topical therapy is first-line. Systemic antibiotics are used only for non-responsive cases or poor compliance.
Deep Pyoderma	Infection breaks through the hair follicle into the dermis and subcutaneous tissue (furunculosis).	Nodules, draining tracts, hemorrhagic crusts, swelling, pain, systemic illness (fever, lethargy).	Mandatory systemic antibiotics guided by culture and sensitivity, combined with adjunctive topical therapy.

Surface Pyoderma

Surface pyoderma is not a true infection of the tissue but rather a bacterial colonization of the skin surface. A classic example is acute moist dermatitis (a "hot spot"), which often develops rapidly in thick-coated breeds after a minor itch (like a flea bite or ear infection) leads to intense self-trauma. Another common form is intertrigo (skin fold pyoderma), occurring in the facial, lip, tail, or vulvar folds of breeds like Bulldogs, Pugs, and French Bulldogs.

Because the bacteria are entirely superficial, systemic antibiotics are completely unnecessary. Treating a hot spot or skin fold dermatitis with oral pills is a clinical error that drives antibiotic resistance without offering any benefit over local clipping, cleaning, and topical drying agents.

Superficial Pyoderma

Superficial pyoderma is the most common presentation. It primarily manifests as bacterial folliculitis, where the infection is centered within the hair follicles. The classic lesions start as small red bumps (papules) that progress to pus-filled pimples (pustules).

As the pustule ruptures and heals, it spreads outward in a circular pattern, leaving a ring of scaling skin with a red center, known as an epidermal collarette. In shorthaired breeds, folliculitis often causes the hair to stand up in small tufts, giving the coat a "moth-eaten" or patchy appearance.

Deep Pyoderma

Deep pyoderma occurs when the hair follicle ruptures internally under the pressure of the infection, releasing bacteria, keratin, and sebum into the surrounding dermis. This trigger causes a severe foreign-body inflammatory reaction called furunculosis.

Deep pyoderma is a serious, painful condition. The skin is typically swollen, purple-red, and thick. It often features nodules that ulcerate and drain bloody, purulent fluid (draining tracts). Dogs with deep pyoderma are often systemically ill, showing lethargy, fever, and regional lymph node enlargement. Deep pyoderma requires aggressive systemic therapy, prolonged treatment courses, and mandatory diagnostic culture testing.

---

The Diagnostic Pathway

An accurate diagnosis is essential to avoid inappropriate treatment. A common clinical mistake is assuming that every red bump on a dog's skin is a bacterial infection. Several other conditions—including fungal infections (ringworm), parasitic infestations (Demodex mites), and sterile autoimmune diseases (such as pemphigus foliaceus)—can mimic the appearance of pyoderma.

A structured diagnostic pathway involves three key steps:

Step 1: Clinical Examination & Staging (Surface vs. Superficial vs. Deep)
                    │
                    ▼
Step 2: Point-of-Care Skin Cytology (Confirm bacteria, rule out yeast/sterile pustules)
                    │
                    ▼
Step 3: Skin Scrape / Trichogram (Rule out Demodex mites)
                    │
                    ▼
Step 4: Culture and Sensitivity (Mandatory if recurrent, non-healing, or suspected MRSP)

1. Point-of-Care Skin Cytology

Skin cytology is the most important diagnostic test in veterinary dermatology. It is a rapid, inexpensive, point-of-care test that should be performed on every patient presenting with skin lesions.

To perform cytology, the veterinarian collects cellular debris from a pustule, under a crust, or from an epidermal collarette. This is done using a glass slide (direct impression), clear acetate tape (tape prep), or a wooden spatula. The sample is stained (typically with a Diff-Quik stain) and examined under a microscope.

Cytology allows the veterinarian to confirm:

• The presence of bacteria: Cocci (spherical bacteria, usually Staphylococcus) or rods (cylindrical bacteria, which suggest a more complicated secondary infection like Pseudomonas or Proteus).
• Inflammatory cells: Active neutrophils, which indicate an active inflammatory response.
• Intracellular bacteria: Observing cocci inside the neutrophils confirms that the bacteria are causing an active infection, rather than simply colonizing the surface.
• The presence of yeast: Malassezia pachydermatis is a common co-pathogen that requires completely different (antifungal) treatment.
• Sterile conditions: Finding neutrophils without any bacteria suggests an autoimmune disease like pemphigus foliaceus, which is treated with immunosuppressants, not antibiotics.

2. Skin Scraping and Trichogram

A skin scrape or a hair pluck (trichogram) is performed to rule out Demodex canis mites. Demodectic mange causes follicular damage that almost always leads to a secondary bacterial folliculitis. If a vet prescribes antibiotics for pyoderma without ruling out Demodex, the infection will temporarily improve, only to return aggressively once the antibiotic course ends because the underlying mite infestation remains uncontrolled. The relationship between mites and skin infections is detailed in the guide on demodectic mange in dogs.

3. Bacterial Culture and Susceptibility Testing

A bacterial culture and susceptibility (C&S) test involves collecting bacteria from an intact pustule or deep tissue fluid and sending it to a reference laboratory. The lab identifies the specific bacterial species and exposes it to various antibiotic discs to determine which drugs can successfully kill it.

A bacterial culture is not mandatory for the very first episode of mild, superficial pyoderma in a dog with no history of antibiotic use. However, a culture is mandatory in the following scenarios:

• Lack of response: The skin lesions do not improve after 2 weeks of empirical treatment.
• Recurrent infections: The pyoderma returns within a few weeks of completing a treatment course.
• Prior antibiotic exposure: The dog has received systemic antibiotics within the past 45 to 60 days.
• Deep pyoderma: The infection is staged as deep (furunculosis).
• Cytology shows rods: Finding rod-shaped bacteria under the microscope suggests an opportunistic Gram-negative infection, which has highly unpredictable resistance patterns.
• Suspected MRSP: The patient or owner has a history of MRSP carriage, or the owner is a healthcare worker.

Prescribing antibiotics for a dog that meets any of these criteria without running a culture is poor medical practice that risks treatment failure and further drives multi-drug resistance.

---

Why does topical-first therapy beat oral antibiotics for superficial pyoderma?

The most important clinical document in modern canine dermatology is the 2025 ISCAID antimicrobial use guideline for canine pyoderma (Loeffler et al., Veterinary Dermatology 2025), which builds on the earlier World Association for Veterinary Dermatology (WAVD) consensus. It states explicitly that topical antimicrobial therapy alone is the treatment of choice for surface and superficial pyoderma, and that systemic antibiotics are reserved for deep pyoderma or superficial cases where topical therapy is not effective.

Historically, topical therapy was viewed as an optional "add-on" to oral antibiotics. We now know that daily topical therapy is equally effective as a systemic antibiotic (amoxicillin-clavulanate) in resolving superficial pyoderma, even when the infection is caused by methicillin-resistant strains (MRSP).

There are three major clinical advantages to a topical-first strategy:

1. Extremely High Local Concentrations

When you give an oral antibiotic, the drug must be absorbed by the gut, enter the bloodstream, and distribute throughout the body, eventually reaching the skin. The concentration of the drug that reaches the skin surface is relatively low.

When you apply a medicated shampoo or spray directly to the skin, you deliver an extremely high local concentration of the active ingredient. For example, a 4% chlorhexidine shampoo delivers a concentration of 40,000 micrograms per milliliter directly to the target area. This concentration is hundreds of times higher than the minimum inhibitory concentration (MIC) of even highly resistant bacteria, effectively overcoming many resistance mechanisms.

2. Efficacy Against MRSP

Topical antiseptics like chlorhexidine work by physically disrupting the bacterial cell membrane, a mechanical mechanism of action. Because it does not rely on metabolic pathways within the cell, chlorhexidine is equally effective against methicillin-susceptible (MSSP) and methicillin-resistant (MRSP) staph. Whether your dog has a highly resistant "superbug" or a standard staph strain, chlorhexidine kills them all.

3. Preserving the Microbiome and Reducing Systemic Toxicity

Oral antibiotics are systemic, meaning they kill bacteria throughout your dog's body, including the beneficial microflora of the gastrointestinal tract. This dysbiosis can persist for weeks or months after treatment, leading to vomiting, diarrhea, and long-term metabolic shifts.

Systemic drugs also carry risks of liver and kidney toxicity, and certain agents (like fluoroquinolones) can cause cartilage damage in growing puppies. Topical therapy avoids these systemic risks entirely, keeping the treatment localized to the skin.

The Topical Protocol: Shampoos, Wipes, and Sprays

To achieve success with topical-first therapy, you must execute the protocol correctly. Antiseptics require adequate contact time to penetrate the bacterial cell wall.

• Medicated Bathing (2–3 times per week):
  1. Use a shampoo containing 2% to 4% chlorhexidine (often combined with 2% miconazole to address co-existing Malassezia yeast).
  2. Wet the coat thoroughly with cool or lukewarm water. Hot water can worsen itching and inflammation.
  3. Lather the shampoo into the coat, ensuring it reaches the skin, especially in heavily affected areas (belly, groin, paws).
  4. Allow 10 minutes of contact time. This is the most critical step. If you rinse the shampoo off immediately, it will fail. Use a timer.
  5. Rinse thoroughly with cool water. Any leftover residue can cause skin irritation.
  6. Pat the skin dry with a clean towel; avoid vigorous rubbing, which can damage fragile skin.
• Targeted Daily Therapy (Non-bath days): On the days your dog does not receive a bath, apply chlorhexidine sprays, mousses, or wipes directly to the lesions once or twice daily. This maintains a high antiseptic concentration on the skin and prevents the bacteria from recolonizing. Wipes are particularly useful for skin folds, lip folds, and between the toes.

---

Which systemic antibiotics are used, and what is the tier system?

If your dog has deep pyoderma, or if compliance issues (such as a large, uncooperative dog or physical limitations of the owner) prevent topical therapy, systemic oral antibiotics may be necessary.

Veterinarians classify systemic antibiotics into three tiers, as outlined in the current ISCAID pyoderma guidelines. This tiered system is designed to protect critical human pathogens while ensuring dogs receive effective treatment.

TIER 1: First-Line Empirical (MSSP Suspected)
├── Cephalexin (Oral)
├── Cefpodoxime (Oral)
├── Amoxicillin-clavulanate (Oral)
└── Clindamycin (Oral)

TIER 2: Culture-Guided Only (MRSP / Resistant Cases)
├── Cefovecin (Convenia - Long-acting Injectable)
├── Enrofloxacin (Oral Fluoroquinolone)
└── Marbofloxacin (Oral Fluoroquinolone)

TIER 3: Protected Reserves (Severe Multidrug Resistance Only)
├── Gentamicin (Parenteral)
├── Amikacin (Parenteral)
└── Chloramphenicol (Oral - High human toxicity risk)

Tier 1: First-Line Drugs

Tier 1 drugs are the standard choices for empirical treatment (when a culture has not yet been performed but the dog has no risk factors for resistance).

• Cephalexin: A first-generation cephalosporin, cephalexin is the historical workhorse of veterinary dermatology. It is highly effective against susceptible staph and has a wide safety margin.
• Cefpodoxime: A third-generation oral cephalosporin. It is administered once daily (compared to cephalexin's twice-daily dosing), which greatly improves compliance for many owners.
• Amoxicillin-clavulanate: A potentiated penicillin. Standard amoxicillin is useless against S. pseudintermedius because virtually all strains produce beta-lactamase enzymes that destroy the drug. Adding clavulanic acid inhibits these enzymes, restoring efficacy.
• Clindamycin: A lincosamide antibiotic. It penetrates tissues well and is a good option for dogs allergic to penicillins or cephalosporins.

Tier 2: Second-Line (Culture-Only)

Tier 2 drugs should never be prescribed empirically for routine superficial pyoderma. They are reserved for cases where a culture has documented resistance to Tier 1 drugs but susceptibility to Tier 2 agents.

• Cefovecin (Convenia): A long-acting injectable third-generation cephalosporin that provides therapeutic tissue levels for 14 days. Convenia is highly convenient, but it represents a major stewardship challenge. Because it persists in the body at low concentrations for up to 65 days, it exerts prolonged selective pressure that drives bacterial resistance. Empiric use of Convenia for a simple skin infection is inappropriate. The safety and stewardship profile of this injectable is detailed in Convenia side effects and FDA data.
• Fluoroquinolones (Enrofloxacin, Marbofloxacin): These broad-spectrum, highly potent antibiotics are critical for human medicine. In veterinary dermatology, they should be strictly reserved for deep pyoderma cases where culture testing confirms no other oral options exist.

Tier 3: Third-Line (Protected Reserves)

Tier 3 drugs are highly restricted reserve agents. They are used only when a culture document confirms susceptibility only to these agents, and the dog has a life-threatening or severe deep infection.

• Gentamicin & Amikacin: Aminoglycoside antibiotics that require injectable administration and close veterinary monitoring for kidney toxicity (nephrotoxicity) and ear toxicity (ototoxicity).
• Chloramphenicol: An oral antibiotic that carries a rare but fatal risk of irreversible aplastic anemia in humans who handle the tablets. It must be handled with gloves and extreme care.

The duration question: shorter courses, mandatory rechecks

The duration of systemic therapy is where practice has changed most. For years, the standard was a fixed long course — 3 weeks for superficial pyoderma and 6 weeks for deep pyoderma. The 2025 ISCAID guideline explicitly moved away from those fixed durations, citing evidence (Sousa et al., 2022) that they were inherited custom rather than proven necessity.

Current guidance is to start with a shorter initial course and recheck:

• Superficial Pyoderma: Start systemic therapy for about 2 weeks, then schedule a recheck exam. Continue only if lesions have not fully resolved.
• Deep Pyoderma: Start systemic therapy for about 3 weeks, then recheck and extend as needed based on clinical response.

Two duration principles still hold regardless of the starting course. First, do not stop the moment the skin "looks better" — visible clearing precedes microbiological cure, so stopping early leaves behind the most resilient bacteria and seeds a resistant recurrence. Second, when treatment is extended at recheck, the traditional rule is to continue until 7 to 14 days past complete clinical resolution (7 days for superficial, up to 14 for deep). The decision to stop is made at a follow-up exam, not by the owner at home.

---

Antibiotic Resistance: The Moat of FDA NARMS Data

To understand why the veterinary community is moving away from systemic pills, we must look at the hard data. The FDA’s National Antimicrobial Resistance Monitoring System (NARMS) and the National Animal Health Laboratory Network (NAHLN) collect and track bacterial isolates submitted by veterinary diagnostic laboratories across the United States.

Below is the calculated resistance profile for 13,438 canine Staphylococcus pseudintermedius clinical isolates collected from 2017 through 2024.

Table: Antibiotic Resistance Rates in Canine S. pseudintermedius (FDA NARMS/NAHLN 2017-2024)

Drug Name	Class / Tier	Number of Interpretable Isolates	Number of Resistant Isolates	Resistance Rate (%)
Penicillin	Beta-lactam / Tier 1	13,111	9,640	73.53%
Enrofloxacin	Fluoroquinolone / Tier 2	13,355	5,606	41.98%
Erythromycin	Macrolide / Tier 1	10,796	4,225	39.13%
Clindamycin	Lincosamide / Tier 1	10,788	4,143	38.40%
Oxacillin (Methicillin)	MRSP Surrogate / Tier 1	13,267	4,846	36.53%
Cefovecin (Convenia)	3rd-Gen Cephalosporin / Tier 2	13,249	4,111	31.03%
Cefpodoxime	3rd-Gen Cephalosporin / Tier 1	13,187	2,893	21.94%
Amoxicillin/Clavulanic Acid	Potentiated Penicillin / Tier 1	13,159	2,749	20.89%
Gentamicin	Aminoglycoside / Tier 3	13,369	2,402	17.97%
Cefazolin	1st-Gen Cephalosporin / Tier 1	13,179	1,245	9.45%

Source: FDA NARMS/NAHLN animal pathogen database. Note: Marbofloxacin, Amikacin, and Chloramphenicol are excluded from this table due to high rates (>30%) of Non-Interpretable test outcomes in this specific surveillance feed.

Understanding the Data Skew (Stewardship Disclaimer)

When reviewing these high resistance rates, it is important to understand a critical epidemiological detail: these numbers represent clinical submissions, not the general dog population.

Veterinarians typically submit samples for culture testing only when initial empirical treatments have failed, or when a dog has a history of recurrent infections. Therefore, this dataset is heavily skewed toward complicated, hard-to-treat cases.

The resistance rate of staph in a healthy puppy experiencing their very first skin infection is much lower. However, these numbers represent the "upper bound" of resistance—a clear map of what happens when antibiotics are overused. The data shows:

• Methicillin Resistance (MRSP) is high: At 36.53%, methicillin resistance is a major clinical concern. If a dog has MRSP, it is automatically resistant to all conventional beta-lactam antibiotics, including cephalexin, cefpodoxime, Convenia, and amoxicillin-clavulanate.
• Empirical choices are compromised: Clindamycin (38.40%) and enrofloxacin (41.98%) have high resistance rates in this cohort, meaning they are poor choices for empirical treatment of recurrent cases.
• Convenia resistance is notable: The long-acting injectable cefovecin (Convenia) shows a 31.03% resistance rate. This is significant because Convenia is frequently used as a convenient empirical option for skin infections, yet nearly one-third of the isolates submitted to labs are completely resistant to it.

---

Recurrent Pyoderma: The Root-Cause Ladder

If your dog is treated for pyoderma and it clears up, only to return a few weeks or months later, you are not dealing with a simple skin infection. You are dealing with an underlying skin barrier defect or systemic disease.

In veterinary medicine, we say that "recurrent pyoderma is a symptom, not a diagnosis." If you treat recurrent pyoderma with repeated courses of oral antibiotics without identifying and controlling the underlying cause, you will drive antibiotic resistance and eventually fail to cure the dog.

To resolve recurrent pyoderma, you must climb the Root-Cause Ladder:

                         [ Level 4: Rare / Complex ]
                         └── Demodicosis, Follicular Dysplasia, Autoimmune Mimics
                                    ▲
                         [ Level 3: Endocrinopathies ]
                         └── Hypothyroidism, Cushing's Disease (Hyperadrenocorticism)
                                    ▲
                         [ Level 2: Primary Allergies ]
                         └── Environmental (Atopy), Food, Flea Allergy Dermatitis
                                    ▲
                         [ Level 1: Compliance / Treatment Gaps ]
                         └── Early discontinuation of drugs, low shampoo contact time

Level 1: Compliance and Treatment Gaps

Before assuming your dog has a complex disease, rule out treatment failures:

• Duration too short: Were the antibiotics stopped as soon as the skin looked better, rather than continuing for the required 7 to 14 days past clinical resolution?
• Under-dosing: Was the antibiotic dose calculated incorrectly based on an outdated weight?
• Topical contact time: Was the medicated shampoo rinsed off before the mandatory 10-minute contact time?
• Steroid overuse: Was the dog given oral steroids (like prednisone) or steroid-containing topical creams for itching? Steroids suppress the immune system, making it impossible for the skin to clear the bacterial load.

Level 2: Primary Allergies (The #1 Cause)

Allergies are the most common cause of recurrent pyoderma. Allergic skin is inflamed, itchy, and has a disrupted skin barrier, making it the perfect environment for S. pseudintermedius to overgrow.

• Flea Allergy Dermatitis (FAD): Even a single flea bite can trigger intense itching and secondary pyoderma in an allergic dog. Year-round flea prevention is mandatory for all pyoderma patients.
• Food Allergy (Cutaneous Adverse Food Reaction): An allergy to a protein source in the diet (typically chicken, beef, or dairy). It requires a strict 8-to-12-week elimination diet trial to diagnose.
• Environmental Allergy (Atopic Dermatitis): An allergic reaction to pollens, molds, house dust mites, or grasses. Atopic dermatitis is a lifelong genetic disease that requires long-term immunomodulatory therapy (like Apoquel, Cytopoint, or cyclosporine) to control the itch and protect the skin barrier. The diagnostic pathway and long-term management of allergies are discussed in the canine atopic dermatitis workup.

Level 3: Endocrinopathies (Hormonal Disorders)

Hormonal imbalances alter the skin structure, thin the epidermis, suppress the local immune response, and decrease sebum production, making the skin highly susceptible to bacterial colonization.

• Hypothyroidism: An underactive thyroid gland, common in middle-aged, medium-to-large breed dogs. It causes lethargy, weight gain, symmetrical hair loss, and recurrent skin infections. The diagnostic testing and thyroid supplementation protocol are explained in the guide on hypothyroidism in dogs.
• Cushing's Disease (Hyperadrenocorticism): An overproduction of cortisol by the adrenal glands, common in older dogs. It leads to increased thirst and urination, a pot-bellied appearance, thin skin, blackheads (comedones), mineral deposits in the skin (calcinosis cutis), and chronic, non-healing pyoderma.

---

Frequently Asked Questions

Is canine pyoderma contagious to humans or other pets? No. Staphylococcus pseudintermedius is a species-specific bacteria that is a normal resident of canine skin. It poses an extremely low risk to healthy humans and other pets. Normal hand hygiene is sufficient protection. However, if a human family member is severely immunocompromised or has open wounds, they should avoid direct contact with the dog's lesions.

How long does it take for pyoderma to clear up? Superficial pyoderma typically resolves within 3 to 4 weeks of consistent topical therapy (bathing and daily sprays). When systemic antibiotics are used, current 2025 ISCAID guidance starts the course at about 2 weeks for superficial pyoderma (3 weeks for deep), with a recheck exam to decide whether to extend treatment until 7 to 14 days past complete clinical resolution. Deep pyoderma is much more challenging, often requiring several weeks to months of culture-guided systemic antibiotics to fully resolve.

Why did my vet recommend a skin culture before prescribing an antibiotic? Your vet recommended a culture because staphylococcal resistance is rising. Approximately 36.5% of staph isolates submitted to labs are now methicillin-resistant (MRSP). Running a culture ensures your dog is not given an ineffective antibiotic, which would delay healing, cause unnecessary side effects, and further select for resistant "superbugs."

Can I treat pyoderma with just medicated shampoo, or does my dog need pills? If the pyoderma is surface or superficial (the most common types), medicated shampoo containing 2% to 4% chlorhexidine is the recommended first-line treatment. Clinical studies show that consistent bathing (2–3 times per week with a 10-minute contact time) combined with daily antiseptic sprays/wipes is just as effective as oral antibiotics, without the risk of gastrointestinal side effects or systemic resistance. Systemic pills are reserved for deep infections or cases where bathing is not possible.

Why does my dog's skin infection keep coming back? Pyoderma is almost always a secondary symptom of an underlying trigger. If the infection returns shortly after completing treatment, your dog likely has an uncontrolled primary disease—most commonly environmental or food allergies, flea allergy dermatitis, demodectic mange mites, hypothyroidism, or Cushing's disease. Climbing the root-cause ladder with your vet to identify this trigger is the only way to achieve long-term resolution.

---

Sources

• Loeffler A, Cain CL, Ferrer L, Nishifuji K, Varjonen K, Papich MG, Guardabassi L, Frosini SM, Barker EN, Weese JS. Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID). Veterinary Dermatology 2025;36:234-282. doi:10.1111/vde.13342
• Santoro D. Topical therapy for canine pyoderma: what is new? Journal of the American Veterinary Medical Association 2023;261(S1):S140-S148. https://avmajournals.avma.org/view/journals/javma/261/S1/javma.23.01.0001.xml
• Valentine B. Treating pyoderma without the use of systemic antibiotics. Canadian Veterinary Journal 2019;60(12):1361-1363. https://pmc.ncbi.nlm.nih.gov/articles/PMC6855222
• Today's Veterinary Practice. Topical Treatment of Canine Superficial Pyoderma (Jan/Feb 2024). https://todaysveterinarypractice.com/dermatology/topical-treatment-of-canine-superficial-pyoderma/
• FDA National Antimicrobial Resistance Monitoring System (NARMS) / NAHLN canine clinical-isolate surveillance database (2017-2024 collection years). https://www.fda.gov/animal-veterinary/national-antimicrobial-resistance-monitoring-system
• Loeffler A, Cobb MA, Bond R. Comparison of a chlorhexidine and a benzoyl peroxide shampoo as sole treatment in canine superficial pyoderma. Veterinary Record 2011;169(10):249. doi:10.1136/vr.d4400
• Loeffler A, et al. Reduction in systemic antimicrobial prescribing for canine pyoderma following changes in prescribing legislation and guidelines. Veterinary Record 2024. https://bvajournals.onlinelibrary.wiley.com/journal/20427670
• Hill PB, Lo A, Eden CA, et al. Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animal general practice. Veterinary Dermatology 2006;17(2):135-144. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-3164.2006.00509.x
• Royal Canin Academy. Canine pyoderma: the problem of meticillin resistance. https://academy.royalcanin.com/en/veterinary/canine-pyoderma-the-problem-of-meticillin-resistance
• Merck Veterinary Manual. Pyoderma in Dogs. https://www.merckvetmanual.com/dog-owners/skin-disorders-of-dogs/pyoderma-in-dogs